Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protease, serine 3 (TMPRSS3) is a type II transmembrane serine protease containing a serine protease domain, a transmembrane domain, a low-density lipoprotein receptor class A (LDLRA) domain, and a scavenger receptor cysteine-rich domain. It is essential for the survival and activation of cochlear hair cells and is required for proper hearing. TMPRSS3 mutations cause autosomal recessive nonsyndromic hearing loss (DFNB8/10). It is also expressed in various tissues and is overexpressed in some tumors, including ovarian cancer. TMPRSS3 is involved in proteolytic regulation of ion channels, particularly those important for auditory transduction and cochlear cell maintenance. No drugs specifically target TMPRSS3 clinically, but its genetic variants are used as diagnostic biomarkers for hereditary deafness syndromes.
Not directly drug-targeted; general mechanism is proteolysis of target proteins in cellular and extracellular contexts, impacting ion channel regulation and hair cell survival
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protease, serine 3 (TMPRSS3).